Investigational drug · Phase 2
IPG11406
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "IPG11406"
First trial start
2025
Feb 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IPG11406", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lupus Nephritis
- Moderately to Severely Active Ulcerative Colitis (UC)
Approved drugs for the same conditions: Ulcerative colitis · Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "IPG11406" as an intervention, largest first.
- A Study of IPG11406 Tablets in Participants With Lupus NephritisPivotal-lookingNot yet recruiting
Nanjing Immunophage Biotech Co., LtdIndustry
NCT07937501 · 192 participants (planned) · Start Nov 20, 2026 · Primary completion Nov 20, 2028
Drug: IPG11406 tablet; placebo · For: Lupus Nephritis
Sites: Nanjing, China
- Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)Pivotal-lookingRecruiting
Nanjing Immunophage Biotech Co., LtdIndustry
NCT07535489 · 144 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 1, 2028
Drug: IPG11406; Placebo · For: Moderately to Severely Active Ulcerative Colitis (UC)
Sites: Beijing, China
Nanjing Immunophage Biotech Co., LtdIndustry
NCT06255834 · 66 participants · Start Feb 24, 2024 · Primary completion Dec 30, 2024
Drug: IPG11406 · For: Inflammatory Bowel Diseases
Sites: Hangzhou, China
Nanjing Immunophage Biotech Co., LtdIndustry
NCT06717815 · 24 participants · Start Feb 25, 2025 · Primary completion Jun 8, 2026
Drug: IPG11406 · For: Lupus Nephritis
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- GPR183-mediated immune cell positioning and function: an integrative perspective across ligand gradients, tissue environments, and disease stages.
Lin X, Dong X, Jiang Z, et al. · Front Immunol 2026
Also in development for Lupus Nephritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- Zola-celBMS-986353, CC-97540Phase 33 trials
Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- CRC01Phase 22 trials
Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.